The permeability and safety of two lead compounds, (R)-T6 and (S)-T6, which are selective nicotinic acetylcholine receptor (nAChR) ligands for 7 nAChR and 34 nAChR, respectively, were evaluated in vitro to provide support to move on to preclinical studies. The 7 nAChR is well recognized as a drug target for neurodegenerative diseases while that of 34 nAChR is for drug addiction. The permeability of (R)-T6 and (S)-T6 assessed by parallel artificial membrane permeability assay (PAMPA) indicated high human oral absorption with effective permeability (Pe) of 2.47x10 -6 and 8.99x10 -6 cm/s, respectively. The cytotoxicity and the cardiotoxicity were determined to assess the safety of (R)-T6 and (S)-T6. The cytotoxic IC50 values of (R)-T6 and (S)-T6 on normal HEK 293 cells obtained by MTT assays were 24.98 and 90.93 M, respectively. For cardiac-safety test, the effect on human ether-ago-go-related gene (hERG) potassium channels was determined by fluorescence polarization-based assay, the result suggested that (R)-T6 and (S)-T6 bind to hERG potassium channel but in the same level with the common drugs such as haloperidol and thioridazine. Collectively, (R)-T6 and (S)-T6 exhibited favorable permeability and acceptable safety profile. These preliminary data support the safety and suitability of the (R)-T6 and (S)-T6 to proceed to preclinical animal studies.
INTRODUCTION
A nAChR is a member of Cys-loop ligand-gated ion channel superfamily composed of five subunits surrounding an ion pore. There are at least 12 neuronal subunits which are 2-10 and 2-4 characterized in human and avian systems 1, 2 . The localization and stoichiometry difference of nAChRs lead to functional and pharmacological variance 3, 4 . The important nAChRs found in brain are 7, 42 and 34 subtypes. The 7 and 42 subtypes have the highest expression level in cerebral cortex and hippocampus associated with cognition, memory and behavior 5 . The 7 and 42 subtypes are important drug targets for neurodegenerative diseases including Alzheimer's disease, cognitive deficits of schizophrenia, attention-deficit hyperactivity disorder (ADHD) and Parkinson's disease [6] [7] [8] . The 34 nAChR has been implicated in substance addiction and depression, the 34 subtype is mainly expressed in autonomic ganglia and some brain regions i.e. medial habenula, nucleus interpeduncularis, dorsal medulla, and pineal gland 9 . According to the potential of 7 and 34 nAChRs as drug targets, a number of compounds with different chemotypes have been developed to act on these targets. For instance, several triazole-containing molecules and triazole-quinuclidine compounds have been previously reported as 7, 42 and 34 nAChR ligands [10] [11] [12] [13] . Recently, the selective binding of triazole-quinuclidine compounds to the nAChR subtypes was reported to be governed by the stereocenter at position 3 of quinuclidine scaffold. The (R)-enantiomers showed subtype selectivity for 7 nAChR, whereas the (S)-enantiomers predominantly binds to 34 nAChR. (R)-and (S)-enantiomers of compound T6 (Figure 1 ) are the promising lead compounds based on the high selectivity and affinity. (R)-T6 has high affinity to 7 nAChR (Ki 33.2 nM) and selective for 7 nAChR over 34 (33 fold) and 42 subtypes (193 fold), whereas (S)-T6 having high affinity to 34 subtype with Ki of 7.17 nM, is selective to 34 nAChR over 7 and 42 subtypes 21 and 75 fold, respectively 13 . Herein, the preliminary studies on the permeability and toxicity of the enantiomers of compound T6 were carried out to provide data to support further preclinical studies in animal models. 
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MATERIALS AND METHODS
Test compounds T6
(R)-T6 and (S)-T6 were synthesized by the previously described method 13 . In brief, the terminal alkyne and quinuclidine azide were prepared at first before reacting these two prepared reagents with click chemistry to yield triazolequinuclidine compound. For the alkyne part, 4-fluorobenzyl chloride was reacted with 3-hydroxyphenylacetylene and K2CO3 in acetonitrile at 80 C for 6 h (Scheme 1a) and purified by SiO2 column chromatography using CHCl3/hexane (50/50) as a mobile phase to yield 1-ethynyl-3-((4-fluorobenzyl)oxy)benzene as pale colorless oil. For the (R)-and (S)-quinuclidine azides, trifluoromethanesulfonic anhydride was added dropwise into a solution of sodium azide in the mixed solvent of water and toluene. The reaction mixture was vigorously stirred at 0 C for 2 h and extracted with toluene to yield trifluoromethanesulfonylazide (TfN3). The freshly prepared TfN3 in toluene was added into the reaction mixture of (R) or (S) of 3-aminoquinuclidine dihydrochloride, K2CO3, CuSO4·5H2O in water and methanol and was vigorously stirred at room temperature for 12 h (Scheme 1b). After that, it was poured into water and extracted with CH2Cl2 before washing with brine solution and drying over anhydrous Na2SO4. The solvent was removed under reduced pressure to yield (R)-azidoquinuclidine and (S)-azidoquinuclidine as yellow liquid and used without purification.
To obtain the target triazole-quinuclidine T6, 1-ethynyl-3-((4-fluorobenzyl)oxy)benzene in t-BuOH was added into (R)-azidoquinuclidine or (S)-azidoquinuclidine in THF. Then, CuSO4·5H2O and sodium ascorbate in water were added and stirred at room temperature for 12 h (Scheme 1c) before extracted with CH2Cl2. The organic layer was washed with brine solution and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure and purified by SiO2 column chromatography using MeOH/CH2Cl2 (20/80) as a mobile phase to yield (R)-T6 and (S)-T6 as a white solid. 14 The permeability of test compound was evaluated by parallel artificial membrane permeability assay (PAMPA) (Corning, USA). The Corning Gentest TM Pre-coated PAMPA Plate System (Cat. No. 353015) which composed of a 96-well plate/insert system was used to perform the permeability assays. Two compartments (donor and receiver wells) are separated by a polyvinylidene fluoride (PVDF) plate pre-coated with a phospholipid-oil-phospholipid tri-layer consisting of DOPC phospholipids. Test compounds were prepared as 10 mM stock concentration in DMSO and diluted to 200 M working solution with phosphate buffer solution (PBS), pH 7.4. The test compound (300 L) was added to a receiver plate. Then, PBS (200 L) was added into a filter plate before placing the filter plate on the receiver plate. The plate was incubated at 25 C for 5 h. After that, the plates were separated. The 150 L of solutions from each well of the receiver and filter plates were drawn to analyze by microplate reader (CLARIOstar, Germany) using UV-transparent plates (Corning, USA).
Permeability test
The permeability (cm/s) was calculated using the following formula:
where VD = donor well volume (0.3 mL), VA = acceptor well volume (0.2 mL), A = filter area (0.3 cm 2 ), t = incubation time (seconds), CA(t) = compound concentration in acceptor well at time t, CD(t) = compound concentration in donor well at time t, Ceq = [(CD(t)xVD)+(CA(t)xVA)]/(VD+VA). was added into an assay plate (384 well untreated low-volume polystyrene microplates) in the absence and presence of potent hERG ligand E-4031 (30 M final concentration). Then, 10 L of hERG Membranes was added followed by 5 L of hERG Tracer Red (1 nM final concentration). The assay plate was mixed on a shaker for 20-30 seconds before covering the plate and incubation for 3 h at room temperature. The assay plate was read on a fluorescence plate reader (Tecan Safire, Switzerland). The excitation and emission values were set at 530 and 585 nm, respectively and the bandwidth was set at 20 nm. The dose response curve was analyzed by using XLfit from IDBS. The assay was run in duplicate and the IC50 was reported.
Cytotoxicity test
RESULTS AND DISCUSSION
The in vitro studies on permeability and safety profiles of two potential lead compounds (R)-T6 and (S)-T6 acting on 7 and 34 nAChRs, respectively were conducted to provide the preliminary data for entering preclinical study in animal models. The in vitro permeability and safety profiles established in the very early stages are essential to reduce drug attrition in the preclinical and late stages of clinical trials.
One of the most important factor of pharmacokinetic parameters is absorption. Several drugs have failed in clinical studies due to absorption problem 17 ; therefore, the prediction of gastrointestinal (GI) permeability of drugs is required in early drug discovery to assess oralabsorption potential of drug candidates. A non-cell based assay, PAMPA was employed to predict the in vivo passive absorption of the target compounds, (R)-and (S)-enantiomers. An artificial PVDF membrane pre-coated with structured layers of phospholipids was applied to simulate lipid bilayer of intestinal epithelial cells in PAMPA model. This in vitro model was selected to measure a compound's passive permeability during lead identification before the preclinical phase because the PAMPA assay is simple, rapid, low-cost and robust compared to the labor-intensive and expensive conventional cellbased assay 18, 19 . However, the cell-based assays such as Caco-2 cells and Mardin-Darby canine kidney (MDCK) as well as in vivo studies are still required in the later preclinical phase to provide additional information on the carrier-mediated transports in the absorption process and metabolism despite the lack of CYP3A4 and low expression of metabolic enzymes and transporters in Caco-2 and MDCK cell lines 20, 21 . Despite the lack of transporters and metabolic enzymes, the PAMPA permeability values appeared to be in good agreement with the Caco-2 and human absorption values 21 . The PAMPA permeability Pe values of (R)-T6 and (S)-T6 are 2.47 x 10 -6 and 8.99 x 10 -6 cm/s, respectively (Table 1) , which are greater than 1.5 x 10 -6 cm/s indicating the high permeability 14 . These data suggested the good oral absorption of (R)-T6 and (S)-T6.
Another factor causing drug failure in clinical trials is a safety profile 17 that (R)-T6 and (S)-T6 were evaluated for cytotoxicity and cardiotoxicity. The in vitro cytotoxicity test in normal HEK 293 cells was performed at first by MTT assay to evaluate the safety of (R)-T6 and (S)-T6 before proceeding to the efficacy test in Table 1 . In vitro permeability and toxicity profiles of (R)-T6 and (S)-T6. the animal models. The 50% inhibition concentrations (IC50) of (R)-T6 and (S)-T6 are 24.98 and 90.93 M, respectively (Table 1, Figure 2 ). The IC50 values of these two compounds are in micromolar range as verapamil (IC50 = 111.9 M), which is a drug used in a human, indicating the safety profile to normal cells of (R)-T6 and (S)-T6. For the cardiotoxicity, a compound that is able to block hERG K + channel tends to cause cardiotoxicity from QT prolongation, which may develop potentially lethal 'torsades-de-pointes' (TdP) arrhythmias leading to sudden death 22 . Hence, the assessment of hERG K + channel is required before starting clinical studies and consequently, the in vitro assays to screen the lead compounds for activity on hERG K + channel is performed early in the lead identification process to reduce the risk of failing in the preclinical study due to the adverse cardiovascular effects, particularly the most serious Tdp in vivo. A number of hERG assays to assess cardiac safety have been developed e.g. patch clamp electrophysiology, radioligand binding assay, liposome flux assay, fluorescence polarization-based (FP) assays 17, [23] [24] [25] [26] [27] . The hERG FP assay was selected because FP assay is fast, simple, inexpensive, reliable, and inexposure to radiation. Nonetheless, the binding data for hERG channel obtained from FP assay showed high correlation to the traditional methods, patch clamp electrophysiology and radioligand binding data 16 . In FP assay, a plane of polarized light will excite a fluorescent tracer molecule such as fluorescein, Texas Red, BODIPY, Cy5 and rhodamines, the polarization of the emitted light will be retained in case a tracer still bound to hERG K + channel. If a test compound can bind to hERG K + channel, light emission from tracer will be depolarized 16 . This method detects a change of a signal occurred when a compound displaces a fluorescence probe binding to hERG K + channel. In the assay, (R)-T6 and (S)-T6 were firstly tested for the polarization and fluorescence interference and no interference of test compounds from nonspecific interaction was observed neither to polarization nor fluorescence values. The IC50 of (R)-T6 and (S)-T6 to hERG K + channel is 486 and 120 nM, respectively (Table 1, Figure 3 ), whereas the IC50 of E-4031, a selective hERG K + channel inhibitor is 12.5 nM. The IC50 of these two compounds to hERG K + channel are in nanomolar range indicating the high binding to hERG channel, but the IC50 values are 3.6-14.7 fold higher than the reported values of terfenadine (IC50 = 33 nM) 16 , a well-known withdrawn antihistamine because of cardiotoxicity 26 , and comparable to antipsychotic drugs, haloperidol (IC50 = 187 nM) and thioridazine (IC50 = 655 nM) 16 . As FP hERG assay is a nonfunctional assay and a possibility of false-positive, the functional cell-based assay and the gold standard electrophysiology assay need to be conducted to confirm hERG safety of (R)-T6 and (S)-T6. In addition, the clinical QT interval prolongation will not occur if hERG IC50 is 30-fold higher than the therapeutic plasma concentration 28 . The further in vivo experiment to get the effective therapeutic plasma concentration should be performed to confirm a safety margin of (R)-T6 and (S)-T6. 
CONCLUSIONS
(R)-T6 and (S)-T6 which are potent and selective 7 and 34 nAChR ligands, respectively can proceed to preclinical studies in animal models on account of the obtained preliminary data showing good permeability and acceptable safety profiles. However, the assessment of cardiotoxicity by other assays needs to be carried out to confirm the safety profile of these two compounds.
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